Evidence map›Paper›PMID 39115069›Full record

ArticleThe New England journal of medicine2024

Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance.

Giselle Salmasi, David L Murray, Anand Padmanabhan

Abstract readLetterCase Reports
In one paragraph

Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026
    Review
  2. Review
  3. Article
  4. Anti-Platelet Factor 4 Antibody Clonal Heterogeneity and MGUS Status in HIT.medRxiv : the preprint server for health sciences · 2026
    Article
  5. Review
  6. Review
  7. Classification of Platelet-Activating Anti-Platelet Factor 4 Disorders.International journal of laboratory hematology · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Anti-Platelet factor 4 immunothrombosis-not just heparin and vaccine triggers.Research and practice in thrombosis and haemostasis · 2025
    Review
  18. Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Giselle SalmasiStanford University Medical Center, Palo Alto, CA.
David L MurrayMayo Clinic College of Medicine and Science, Rochester, MN padmanabhan.anand@mayo.edu.
Anand PadmanabhanMayo Clinic College of Medicine and Science, Rochester, MN padmanabhan.anand@mayo.edu.ORCID 0000-0003-2519-4377

Funding

New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopeniaR01HL158932 · NHLBI · MAYO CLINIC ROCHESTER · PI PADMANABHAN, ANAND · 2021 to 2025
$2.0M
NHLBI NIH HHS HL158932NHLBI NIH HHS R01 HL158932
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsParaproteinemiasThrombocytopeniaVenous ThrombosisAgedAntibodies, MonoclonalBortezomibDexamethasoneFemaleFondaparinuxHumansMaleMesenteric IschemiaMiddle AgedTreatment OutcomeAntibodies, MonoclonalBortezomibdaratumumabDexamethasoneFondaparinux

Identifiers

PMID39115069
PMCPMC11315357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.